Aktuellt
SENASTE
Redeye comments on the preliminary data from Spago Nanomedical’s clinical phase IIa trial SPAGOPIX-02. We are encouraged to learn that the results analyzed by Data Monitoring Committee show that SN132D is well tolerated in patients with endometriosis. At this stage, we have no information about the efficacy. Therefore, we make no changes to our assumptions and reiterate our base case of SEK1.8 per share.
LÄS MER
